Cited by 286Smoking Behavior and CessationPharmacovigilance and Adverse Drug ReactionsCardiac Health and Mental Health

The DOI matches its Crossref record; 34 of the 34 references it cites were found in a registry or an index.

Risk of serious adverse cardiovascular events associated with varenicline: a systematic review and meta-analysis

Open access

Singh, S., Loke, Y. K., Spangler, J. G., Furberg, C. D.·2011·Canadian Medical Association Journal

Open this paper in CoChat — free account Open PDF

Abstract

BACKGROUND: There have been postmarketing reports of adverse cardiovascular events associated with the use of varenicline, a widely used smoking cessation drug. We conducted a systematic review and meta-analysis of randomized controlled trials to ascertain the serious adverse cardiovascular effects of varenicline compared with placebo among tobacco users. METHODS: We searched MEDLINE, EMBASE, the Cochrane Database of Systematic Reviews, websites of regulatory authorities and registries of clinical trials, with no date or language restrictions, through September 2010 (updated March 2011) for published and unpublished studies. We selected double-blind randomized controlled trials of at least one week's duration involving smokers or people who used smokeless tobacco that reported on cardiovascular events (ischemia, arrhythmia, congestive heart failure, sudden death or cardiovascular-related death) as serious adverse events asociated with the use of varenicline. RESULTS: We analyzed data from 14 double-blind randomized controlled trials involving 8216 participants. The trials ranged in duration from 7 to 52 weeks. Varenicline was associated with a significantly increased risk of serious adverse cardiovascular events compared with placebo (1.06% [52/4908] in varenicline group v. 0.82% [27/3308] in placebo group; Peto odds ratio [OR] 1.72, 95% confidence interval [CI] 1.09-2.71; I(2) = 0%). The results of various sensitivity analyses were consistent with those of the main analysis, and a funnel plot showed no publication bias. There were too few deaths to allow meaningful comparisons of mortality. INTERPRETATION: Our meta-analysis raises safety concerns about the potential for an increased risk of serious adverse cardiovascular events associated with the use of varenicline among tobacco users.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.1503/cmaj.110218

Cites

34 of 34 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Measuring inconsistency in meta-analyses
Higgins, J. P. T., Thompson, S. G., Deeks, J. J., & Altman, D. G. (2003) · BMJ · doi:10.1136/bmj.327.7414.557 · Cited by 63,139
What to add to nothing? Use and avoidance of continuity corrections in meta‐analysis of sparse data
J. Sweeting, M., J. Sutton, A., & C. Lambert, P. (2004) · Statistics in Medicine · doi:10.1002/sim.1761 · Cited by 1,734
Efficacy of Varenicline, an α4β2 Nicotinic Acetylcholine Receptor Partial Agonist, vs Placebo or Sustained-Release Bupropion for Smoking Cessation<SUBTITLE>A Randomized Controlled Trial</SUBTITLE>
Jorenby, D. E. (2006) · JAMA · doi:10.1001/jama.296.1.56 · Cited by 1,635
Varenicline, an α4β2 Nicotinic Acetylcholine Receptor Partial Agonist, vs Sustained-Release Bupropion and Placebo for Smoking Cessation<SUBTITLE>A Randomized Controlled Trial</SUBTITLE>
Gonzales, D. (2006) · JAMA · doi:10.1001/jama.296.1.47 · Cited by 1,361
The Effects of a Smoking Cessation Intervention on 14.5-Year Mortality: A Randomized Clinical Trial
Anthonisen, N. R., Skeans, M. A., Wise, R. A., Manfreda, J., Kanner, R. E., Connett, J. E., & for the Lung Health Study Research Group* (2005) · Annals of Internal Medicine · doi:10.7326/0003-4819-142-4-200502150-00005 · Cited by 1,237
Much ado about nothing: a comparison of the performance of meta-analytical methods with rare events
Bradburn, M. J., Deeks, J. J., Berlin, J. A., & Russell Localio, A. (2007) · Statistics in Medicine · doi:10.1002/sim.2528 · Cited by 938
Nicotine receptor partial agonists for smoking cessation
Hey, K., Lancaster, T., & Bala, M. (2006) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd006103 · Cited by 866
Nicotine receptor partial agonists for smoking cessation
Cahill, K., Stead, L., & Lancaster, T. (2007) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd006103.pub2 · Cited by 747
Effect of Maintenance Therapy With Varenicline on Smoking Cessation<SUBTITLE>A Randomized Controlled Trial</SUBTITLE>
Tonstad, S. (2006) · JAMA · doi:10.1001/jama.296.1.64 · Cited by 660
Varenicline Is a Partial Agonist at α4β2 and a Full Agonist at α7 Neuronal Nicotinic Receptors
Mihalak, K. B., Carroll, F. I., & Luetje, C. W. (2006) · Molecular Pharmacology · doi:10.1124/mol.106.025130 · Cited by 558

Flagged first, then by citations

Show all 33 references

Research works printed but not linked: 2

Josefberg H. Approval package for: application number NDA 21- 928 [clinical safety review: varenicline tartrate]. Rockville (MD): US Food and Drug Administration, Center for Drug Evaluation and Research; 2006. p. 277, 402. Available: www .accessdata .fda .gov /drugsatfda _docs /nda /2006 /021928 _s000 _Chantix _MedR .pdf (ac cessed 2011 Apr. 14).
Montastruc G, Degand B, Montastruc JL, et al. Cardiac arrest with varenicline: a case report [article in French]. Therapie 2009; 64: 65-6.

Sorted by citations

European Guidelines on cardiovascular disease prevention in clinical practice (version 2012)
Authors/Task Force Members:, Perk, J., De Backer, G., Gohlke, H., Graham, I., Reiner, Ž., Verschuren, M., Albus, C., Benlian, P., Boysen, G., et al. (2012) · European Heart Journal · doi:10.1093/eurheartj/ehs092 · Cited by 8,490
2013 ESC guidelines on the management of stable coronary artery disease
Task Force Members, Montalescot, G., Sechtem, U., Achenbach, S., Andreotti, F., Arden, C., Budaj, A., Bugiardini, R., Crea, F., Cuisset, T., et al. (2013) · European Heart Journal · doi:10.1093/eurheartj/eht296 · Cited by 4,510
European guidelines on cardiovascular disease prevention in clinical practice: executive summary
Graham, I., Atar, D., Borch‐Johnsen, K., Boysen, G., Burell, G. K., Cífková, R., Dallongeville, J., Backer, G. D., Ebrahim, S. B. J., Gjelsvik, B., et al. (2007) · European Heart Journal · doi:10.1093/eurheartj/ehm316 · Cited by 3,865
Breast Cancer, Version 4.2017, NCCN Clinical Practice Guidelines in Oncology
Gradishar, W. J., Anderson, B. O., Balassanian, R., Blair, S. L., Burstein, H. J., Cyr, A. E., ELIAS, A. D., Farrar, W. B., Forero, A., Giordano, S. H., et al. (2018) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2018.0012 · Cited by 1,612
2016 European Guidelines on cardiovascular disease prevention in clinical practice
Authors/Task Force Members, Piepoli, M. F., Hoes, A. W., Agewall, S., Albus, C., Brotons, C., Catapano, A. L., Cooney, M. T., Corrà, U., Cosyns, B., et al. (2016) · European Journal of Preventive Cardiology · doi:10.1177/2047487316653709 · Cited by 1,435
Pharmacological interventions for smoking cessation: an overview and network meta-analysis
Cahill, K., Stevens, S., Perera, R., & Lancaster, T. (2013) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd009329.pub2 · Cited by 1,243
Nicotine receptor partial agonists for smoking cessation
Cahill, K., Stead, L., & Lancaster, T. (2007) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd006103.pub2 · Cited by 747
European Guidelines on cardiovascular disease prevention in clinical practice (version 2012)
Perk, J., Backer, G. D., Gohlke, H., Graham, I. M., Reiner, Ž., Verschuren, W. M. M., Albus, C., Benlian, P., Boysen, G., Cífková, R., et al. (2012) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2012.05.007 · Cited by 702
Testosterone therapy and cardiovascular events among men: a systematic review and meta-analysis of placebo-controlled randomized trials
Xu, L., Freeman, G., Cowling, B. J., & Schooling, C. M. (2013) · BMC Medicine · doi:10.1186/1741-7015-11-108 · Cited by 569
Updated Cardiovascular Prevention Guideline of the Brazilian Society of Cardiology - 2019
Précoma, D. B., de Oliveira, G. M. M., Simão, A. F. L., Dutra, Ó. P., Coelho-Filho, O. R., Izar, M. C. D. O., Póvoa, R., Giuliano, I. D. C. B., Filho, A. C. D. A., Machado, C. A., et al. (2019) · Arquivos Brasileiros de Cardiologia · doi:10.5935/abc.20190204 · Cited by 507
Nicotine receptor partial agonists for smoking cessation
Cahill, K., Lindson-Hawley, N., Thomas, K. H., Fanshawe, T. R., & Lancaster, T. (2016) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd006103.pub7 · Cited by 433
Cardiovascular Events Associated With Smoking Cessation Pharmacotherapies
Mills, E. J., Thorlund, K., Eapen, S., Wu, P., & Prochaska, J. J. (2013) · Circulation · doi:10.1161/circulationaha.113.003961 · Cited by 413
2018 ACC Expert Consensus Decision Pathway on Tobacco Cessation Treatment
Barua, R. S., Rigotti, N. A., Benowitz, N. L., Cummings, K. M., Jazayeri, M., Morris, P. B., Ratchford, E. V., Sarna, L., Stecker, E. C., & Wiggins, B. S. (2018) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2018.10.027 · Cited by 391
European Guidelines on Cardiovascular Disease Prevention in Clinical Practice (Version 2012)
Perk, J., Backer, G. D., Gohlke, H., Graham, I. M., Reiner, Ž., Verschuren, W. M. M., Albus, C., Benlian, P., Boysen, G., Cífková, R., et al. (2012) · International Journal of Behavioral Medicine · doi:10.1007/s12529-012-9242-5 · Cited by 319
European Guidelines on cardiovascular disease prevention in clinical practice (version 2012): The Fifth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of nine societies and by invited experts). Developed with the special contribution of the European Association for Cardiovascular Prevention & Rehabilitation (EACPR)
Authors/Task Force Members: Joep Perk (Chairperson) (Sweden)*, G. D. B. (. (2012) · European Journal of Preventive Cardiology · doi:10.1177/2047487312450228 · Cited by 863
Drug safety assessment in clinical trials: methodological challenges and opportunities
Singh, S., & Loke, Y. K. (2012) · Trials · doi:10.1186/1745-6215-13-138 · Cited by 237
Self-citation
The Past, Present, and Future of Nicotine Addiction Therapy
Prochaska, J. J., & Benowitz, N. L. (2015) · Annual Review of Medicine · doi:10.1146/annurev-med-111314-033712 · Cited by 245
Supporting smoking cessation: a guide for health professionals.
Zwar, N. A., RICHMOND, R. L., Borland, R., Peters, M. J., Litt, J., Bell, J., Caldwell, B., & Ferretter, I. T. (2012) · Cited by 215
Risk of cardiovascular serious adverse events associated with varenicline use for tobacco cessation: systematic review and meta-analysis
Prochaska, J. J., & Hilton, J. F. (2012) · BMJ · doi:10.1136/bmj.e2856 · Cited by 202
Managing tobacco use: the neglected cardiovascular disease risk factor
Rigotti, N. A., & Clair, C. (2013) · European Heart Journal · doi:10.1093/eurheartj/eht352 · Cited by 190
I Diretriz Brasileira de Prevenção Cardiovascular
Simão, A., Précoma, D., Andrade, J., Filho, H. C., Saraiva, J., Oliveira, G., Murro, A., Campos, A., Alessi, A., Avezum, Á., et al. (2013) · Arquivos Brasileiros de Cardiologia · doi:10.5935/abc.2013s012 · Cited by 186
Nicotine receptor partial agonists for smoking cessation
Cahill, K., Stead, L. F., & Lancaster, T. (2012) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd006103.pub6 · Cited by 177
Tobacco addiction and the dysregulation of brain stress systems
Bruijnzeel, A. W. (2012) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2012.02.015 · Cited by 181
Strategies to Help a Smoker Who Is Struggling to Quit
Rigotti, N. A. (2012) · JAMA · doi:10.1001/jama.2012.13043 · Cited by 169
Risk of neuropsychiatric adverse events associated with varenicline: systematic review and meta-analysis
Thomas, K. H., Martin, R. M., Knipe, D. W., Higgins, J. P. T., & Gunnell, D. (2015) · BMJ · doi:10.1136/bmj.h1109 · Cited by 155
Smoking cessation medicines and e-cigarettes: a systematic review, network meta-analysis and cost-effectiveness analysis
Thomas, K. H., Dalili, M. N., López-López, J. A., Keeney, E., Phillippo, D., Munafo, M. R., Stevenson, M., Caldwell, D. M., & Welton, N. J. (2021) · Health Technology Assessment · doi:10.3310/hta25590 · Cited by 163
Suicidal Behavior and Depression in Smoking Cessation Treatments
Moore, T. J., Furberg, C. D., Glenmullen, J., Maltsberger, J. T., & Singh, S. (2011) · PLoS ONE · doi:10.1371/journal.pone.0027016 · Cited by 150
Self-citation
Smoking cessation, version 1.2016, NCCN clinical practice guidelines in oncology
Shields, P. G., Herbst, R. S., Arenberg, D., Benowitz, N. L., Bierut, L., Luckart, J. B., Cinciripini, P., Collins, B., David, S., Davis, J., et al. (2016) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2016.0152 · Cited by 146
EPA guidance on tobacco dependence and strategies for smoking cessation in people with mental illness
Rüther, T., Bobes, J., De Hert, M., Svensson, T. H., Mann, K., Batra, A., Gorwood, P., & Möller, H. J. (2014) · European Psychiatry · doi:10.1016/j.eurpsy.2013.11.002 · Cited by 149
Psychosocial interventions for smoking cessation in patients with coronary heart disease
Barth, J., Jacob, T., Daha, I. C., & Critchley, J. (2015) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd006886.pub2 · Cited by 143
Pharmacotherapy for smoking cessation: pharmacological principles and clinical practice
Aubin, H., Luquiens, A., & Berlin, I. (2014) · British Journal of Clinical Pharmacology · doi:10.1111/bcp.12116 · Cited by 138
Effects of Varenicline and Bupropion Sustained-Release Use Plus Intensive Smoking Cessation Counseling on Prolonged Abstinence From Smoking and on Depression, Negative Affect, and Other Symptoms of Nicotine Withdrawal
Cinciripini, P. M., Robinson, J. D., Karam-Hage, M., Minnix, J. A., Lam, C., Versace, F., Brown, V. L., Engelmann, J. M., & Wetter, D. W. (2013) · JAMA Psychiatry · doi:10.1001/jamapsychiatry.2013.678 · Cited by 136
Varenicline for Smoking Cessation in Hospitalized Patients With Acute Coronary Syndrome
Eisenberg, M. J., Windle, S. B., Roy, N., Old, W. D., Grondin, F. R., Bata, I. R., Iskander, A., Lauzon, C., Srivastava, N. K., Clarke, A., et al. (2015) · Circulation · doi:10.1161/circulationaha.115.019634 · Cited by 133
The Evils of Nicotine
Rinker, B. D. (2013) · Annals of Plastic Surgery · doi:10.1097/sap.0b013e3182764fcd · Cited by 125
Efficacy and Safety of Smoking Cessation Interventions in Patients With Cardiovascular Disease: A Network Meta-Analysis of Randomized Controlled Trials
Suissa, K., Larivière, J., Eisenberg, M. J., Eberg, M., Gore, G. C., Grad, R., Joseph, L., Reynier, P. M., & Filion, K. B. (2017) · Circulation: Cardiovascular Quality and Outcomes · doi:10.1161/circoutcomes.115.002458 · Cited by 109
Cardiovascular and neuropsychiatric risks of varenicline: a retrospective cohort study
Kotz, D., Viechtbauer, W., Simpson, C. R., van Schayck, O. C. P., West, R., & Sheikh, A. (2015) · The Lancet Respiratory Medicine · doi:10.1016/s2213-2600(15)00320-3 · Cited by 105
Bupropion for Smoking Cessation in Patients Hospitalized With Acute Myocardial Infarction
Eisenberg, M. J., Grandi, S. M., Gervais, A., O’Loughlin, J. L., Paradis, G., Rinfret, S., Sarrafzadegan, N., Sharma, S., Lauzon, C., Yadav, R. K., et al. (2013) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2012.08.1030 · Cited by 103
2013 ESC GUIDELINES ON THE MANAGEMENT OF STABLE CORONARY ARTERY DISEASE
Montalescot, G., Sechtem, U. P., Achenbach, S., Andreotti, F., Arden, C., Budaj, A., Bugiardini, R., Crea, F., Cuisset, T., Mario, C. D., et al. (2014) · Russian Journal of Cardiology · doi:10.15829/1560-4071-2014-7-7-79 · Cited by 106
Prevention and Treatment of Tobacco Use
Kalkhoran, S. M., Benowitz, N. L., & Rigotti, N. A. (2018) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2018.06.036 · Cited by 108
Smoking and depression--a review.
Mendelsohn, C. P. (2012) · PubMed · Cited by 92
Supporting smoking cessation
Zwar, N. A., Mendelsohn, C. P., & RICHMOND, R. L. (2014) · BMJ · doi:10.1136/bmj.f7535 · Cited by 93
Exploring Issues of Comorbid Conditions in People Who Smoke: Table 1.
Rojewski, A. M., Baldassarri, S. R., Cooperman, N. A., Gritz, E. R., Leone, F. T., Piper, M. E., Toll, B. A., & Warren, G. W. (2016) · Nicotine & Tobacco Research · doi:10.1093/ntr/ntw016 · Cited by 87
Mind–body practices: An alternative, drug-free treatment for smoking cessation? A systematic review of the literature
Carim-Todd, L., Mitchell, S. H., & Oken, B. S. (2013) · Drug and Alcohol Dependence · doi:10.1016/j.drugalcdep.2013.04.014 · Cited by 82
What is the clinical effectiveness and cost-effectiveness of cytisine compared with varenicline for smoking cessation? A systematic review and economic evaluation
Leaviss, J., Sullivan, W., Ren, S., Everson-Hock, E., Stevenson, M., Stevens, J., Strong, M., & Cantrell, A. J. (2014) · Health Technology Assessment · doi:10.3310/hta18330 · Cited by 78
Definition of Best Medical Treatment in Asymptomatic and Symptomatic Carotid Artery Stenosis
Paraskevas, K. I., Mikhailidis, D. P., Veith, F. J., & Spence, J. D. (2015) · Angiology · doi:10.1177/0003319715624526 · Cited by 80
Smoking Cessation, Version 3.2022, NCCN Clinical Practice Guidelines in Oncology
Shields, P. G., Bierut, L. J., Arenberg, D. A., Balis, D. S., Cinciripini, P. M., Davis, J. M., Edmondson, D. M., Feliciano, J., Hitsman, B. L., Hudmon, K. S., et al. (2023) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2023.0013 · Cited by 83
Big Health Data and Cardiovascular Diseases: A Challenge for Research, an Opportunity for Clinical Care
Silverio, A., Cavallo, P., Rosa, R. D., & Galasso, G. (2019) · Frontiers in Medicine · doi:10.3389/fmed.2019.00036 · Cited by 71
Varenicline and adverse cardiovascular events: a systematic review and meta-analysis of randomized controlled trials.
Sterling, L. H., Windle, S. B., Filion, K. B., Touma, L., & Eisenberg, M. J. (2016) · Journal of the American Heart Association · doi:10.1161/jaha.115.002849 · Cited by 70
How Good Is “Evidence” from Clinical Studies of Drug Effects and Why Might Such Evidence Fail in the Prediction of the Clinical Utility of Drugs?
Naci, H., & Ioannidis, J. P. A. (2014) · The Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev-pharmtox-010814-124614 · Cited by 70
Safety and Tolerability of Varenicline Tartrate (Champix ® /Chantix ® ) for Smoking Cessation in HIV-Infected Subjects: A Pilot Open-Label Study
Cui, Q., Robinson, L. L., Elston, D., Smaill, F., Cohen, J., Quan, C., McFarland, N., Thabane, L., McIvor, A., Zeidler, J. G., et al. (2011) · AIDS Patient Care and STDs · doi:10.1089/apc.2011.0199 · Cited by 68
Smoking cessation in patients with respiratory disease: existing treatments and future directions
Rigotti, N. A. (2013) · The Lancet Respiratory Medicine · doi:10.1016/s2213-2600(13)70063-8 · Cited by 66
Varenicline: mode of action, efficacy, safety and accumulated experience salient for clinical populations
Tonstad, S., Arons, C., Rollema, H., Berlin, I., Hájek, P., Fagerström, K. O., Els, C., McRae, T. D., & Russ, C. (2020) · Current Medical Research and Opinion · doi:10.1080/03007995.2020.1729708 · Cited by 66
Big biomedical data and cardiovascular disease research: opportunities and challenges
Denaxas, S., & Morley, K. I. (2015) · European Heart Journal - Quality of Care and Clinical Outcomes · doi:10.1093/ehjqcco/qcv005 · Cited by 66
Effect of Nicotine Replacement Therapy on Cardiovascular Outcomes After Acute Coronary Syndromes
Woolf, K. J., Zabad, M. N., Post, J. M., McNitt, S. A., Williams, G. C., & Bisognano, J. D. (2012) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2012.05.028 · Cited by 61
Effectiveness of a preventive cardiology programme for high CVD risk persistent smokers: the EUROACTION PLUS varenicline trial
Jennings, C. S., Kotseva, K., Bacquer, D. D., Hoes, A. W., Velasco, J. D., Brusaferro, S., Mead, A., Jones, J. L., Tonstad, S., Wood, D., et al. (2014) · European Heart Journal · doi:10.1093/eurheartj/ehu051 · Cited by 61
Treatment of Tobacco Dependence
Batra, A. (2011) · Deutsches Ärzteblatt international · doi:10.3238/arztebl.2011.0555 · Cited by 56
Use of varenicline for smoking cessation and risk of serious cardiovascular events: nationwide cohort study
Svanström, H., Pasternak, B., & Hviid, A. P. (2012) · BMJ · doi:10.1136/bmj.e7176 · Cited by 52
How confidence intervals become confusion intervals
McCormack, J. P., Vandermeer, B., & Allan, G. M. (2013) · BMC Medical Research Methodology · doi:10.1186/1471-2288-13-134 · Cited by 51
Adapting Smoking Cessation Treatment According to Initial Response to Precessation Nicotine Patch
Rose, J. E., & Behm, F. M. (2013) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2013.12070919 · Cited by 51
South African tobacco smoking cessation clinical practice guideline
van Zyl-Smit, R. N., Allwood, B., Stickells, D., Symons, G., Abdool-Gaffar, S., Murphy, K., Lalloo, U., Vanker, A., Dheda, K. U. J., & Richards, G. A. (2013) · South African Medical Journal · doi:10.7196/samj.7484 · Cited by 51
AAV-Directed Persistent Expression of a Gene Encoding Anti-Nicotine Antibody for Smoking Cessation
Hicks, M. J., Rosenberg, J. B., De, B. P., Pagovich, O. E., Young, C. N., Qiu, J., Kaminsky, S. M., Hackett, N. R., Worgall, S., Janda, K. D., et al. (2012) · Science Translational Medicine · doi:10.1126/scitranslmed.3003611 · Cited by 48
Effect of Smoking Reduction Therapy on Smoking Cessation for Smokers without an Intention to Quit: An Updated Systematic Review and Meta-Analysis of Randomized Controlled
Wu, L., Sun, S., He, Y., & Zeng, J. (2015) · International Journal of Environmental Research and Public Health · doi:10.3390/ijerph120910235 · Cited by 48
Tabakentwöhnung bei COPD
Andreas, S., Batra, A., Behr, J., Chenot, J., Gillissen, A., Hering, T., Herth, F. J. F., Kreuter, M., Meierjürgen, R., Mühlig, S., et al. (2014) · Pneumologie · doi:10.1055/s-0034-1365052 · Cited by 46
Drug interaction networks: an introduction to translational and clinical applications
Azuaje, F. J. (2012) · Cardiovascular Research · doi:10.1093/cvr/cvs289 · Cited by 48
New Pharmacological Agents to Aid Smoking Cessation and Tobacco Harm Reduction: What Has Been Investigated, and What Is in the Pipeline?
Beard, E., Shahab, L., Cummings, D. M., Michie, S., & West, R. (2016) · CNS Drugs · doi:10.1007/s40263-016-0362-3 · Cited by 44
Safety of Varenicline Among Smokers Enrolled in the Lung HIV Study
Ferketich, A. K., Diaz, P., Browning, K. K., Lu, B., Koletar, S. L., Reynolds, N. R., & Wewers, M. E. (2012) · Nicotine & Tobacco Research · doi:10.1093/ntr/nts121 · Cited by 44
Cardiovascular Safety of Varenicline
Ware, J. H., Vetrovec, G. W., Miller, A. B., Tosh, A. V., Gaffney, M., Yunis, C., Arteaga, C., & BORER, J. S. (2013) · American Journal of Therapeutics · doi:10.1097/mjt.0b013e31828d455b · Cited by 44
Smoking Cessation After Acute Myocardial Infarction
Benowitz, N. L., & Prochaska, J. J. (2013) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2012.11.017 · Cited by 43
Smoking abstinence 1 year after acute coronary syndrome: follow-up from a randomized controlled trial of varenicline in patients admitted to hospital
Windle, S. B., Dehghani, P., Roy, N., Old, W. D., Grondin, F. R., Bata, I. R., Iskander, A., Lauzon, C., Srivastava, N. K., Clarke, A., et al. (2018) · Canadian Medical Association Journal · doi:10.1503/cmaj.170377 · Cited by 42
Cannabinoid-1 receptor (CB1R) blockers as medicines: beyond obesity and cardiometabolic disorders to substance abuse/drug addiction with CB1R neutral antagonists
Janero, D. R. (2012) · Expert Opinion on Emerging Drugs · doi:10.1517/14728214.2012.660916 · Cited by 41
Cardiovascular and Neuropsychiatric Events after Varenicline Use for Smoking Cessation
Gershon, A. S., Campitelli, M. A., Hawken, S., Victor, C. J., Sproule, B. A., Kurdyak, P. A., & Selby, P. L. (2017) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.201706-1204oc · Cited by 41
Low incidence of adverse events following varenicline initiation among opioid dependent smokers with comorbid psychiatric illness
Nahvi, S., Wu, B. B., Richter, K. P., Bernstein, S. L., & Arnsten, J. H. (2013) · Drug and Alcohol Dependence · doi:10.1016/j.drugalcdep.2012.12.026 · Cited by 48
Varenicline for smoking cessation: a narrative review of efficacy, adverse effects, use in at-risk populations, and adherence
Ebbert, J. O., Burke, M. V., & Hays, J. T. (2016) · Patient Preference and Adherence · doi:10.2147/ppa.s83469 · Cited by 44
Drugs currently in Phase II clinical trials for cocaine addiction
Kim, J. H., & Lawrence, A. J. (2014) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.2014.915312 · Cited by 40
A Double-Blind Placebo-Controlled Randomized Trial of Varenicline for Smokeless Tobacco Dependence in India
Jain, R., Jhanjee, S., Jain, V., Gupta, T., Mittal, S., Goelz, P. M., Wileyto, E. P., & Schnoll, R. A. (2013) · Nicotine & Tobacco Research · doi:10.1093/ntr/ntt115 · Cited by 36
Varenicline-assisted smoking cessation decreases oxidative stress and restores endothelial function
Kato, T., Umeda, A., Miyagawa, K., Takeda, H., Adachi, T., Toyoda, S., Taguchi, I., Inoue, T., & Node, K. (2014) · Hypertension Research · doi:10.1038/hr.2014.52 · Cited by 37
Varenicline and neuronal nicotinic acetylcholine receptors: A new approach to the treatment of co‐occurring alcohol and nicotine addiction?
Nocente, R., Vitali, M., Balducci, G., Enea, D., Kranzler, H. R., & Ceccanti, M. (2013) · American Journal on Addictions · doi:10.1111/j.1521-0391.2013.12037.x · Cited by 37
Methodological issues in observational studies and non-randomized controlled trials in oncology in the era of big data
Tanaka, S., Tanaka, S., & Kawakami, K. (2015) · Japanese Journal of Clinical Oncology · doi:10.1093/jjco/hyu220 · Cited by 36
CC 4, a dimer of cytisine, is a selective partial agonist at α4β2/α6β2 nAChR with improved selectivity for tobacco smoking cessation
Sala, M., Braida, D., Pucci, L., Manfredi, I., Marks, M. J., Wageman, C. R., Grady, S. R., Loi, B., Fucile, S., Fasoli, F., et al. (2012) · British Journal of Pharmacology · doi:10.1111/j.1476-5381.2012.02204.x · Cited by 36
Outcomes of deep brain stimulation surgery for substance use disorder: a systematic review
Hassan, O., Phan, S., Wiecks, N., Joaquin, C., & Bondarenko, V. (2020) · Neurosurgical Review · doi:10.1007/s10143-020-01415-y · Cited by 35
Pharmacological Intervention of Nicotine Dependence
Jain, R., Majumder, P., & Gupta, T. (2013) · BioMed Research International · doi:10.1155/2013/278392 · Cited by 34
Adverse drug reactions reported by consumers for nervous system medications in Europe 2007 to 2011
Aagaard, L., & Hansen, E. H. (2013) · BMC Pharmacology and Toxicology · doi:10.1186/2050-6511-14-30 · Cited by 33
Preclinical Evidence That Activation of Mesolimbic Alpha 6 Subunit Containing Nicotinic Acetylcholine Receptors Supports Nicotine Addiction Phenotype
Brunzell, D. H. (2012) · Nicotine & Tobacco Research · doi:10.1093/ntr/nts089 · Cited by 36
Evaluation of the cardiovascular effects of varenicline in rats
Selçuk, E. B., Süngü, M., Parlakpınar, H., Ermiş, N., Taşlıdere, E., Vardı, N., Yalçınsoy, M., Sağır, M., Polat, A., Karataş, M., et al. (2015) · Drug Design Development and Therapy · doi:10.2147/dddt.s92268 · Cited by 31
The cytisine derivatives, CC4 and CC26, reduce nicotine-induced conditioned place preference in zebrafish by acting on heteromeric neuronal nicotinic acetylcholine receptors
Ponzoni, L., Braida, D., Pucci, L., Donzelli, A., Fasoli, F., Manfredi, I., Papke, R. L., Stokes, C. A., Cannazza, G., Clementi, F., et al. (2014) · Psychopharmacology · doi:10.1007/s00213-014-3619-x · Cited by 30
Cardiovascular Events in Patients taking Varenicline
Harrison‐Woolrych, M., Maggo, S. D. S., Tan, M., Savage, R. L., & Ashton, J. (2011) · Drug Safety · doi:10.2165/11597690-000000000-00000 · Cited by 29
Systematic review of the cost-effectiveness of varenicline vs. bupropion for smoking cessation
Mahmoudi, M., Coleman, C. I., & Sobieraj, D. M. (2012) · International Journal of Clinical Practice · doi:10.1111/j.1742-1241.2011.02877.x · Cited by 28
Patterns of nicotinic receptor antagonism II: Cardiovascular effects in rats
Jutkiewicz, E. M., Rice, K. C., Carroll, F. I., & Woods, J. H. (2013) · Drug and Alcohol Dependence · doi:10.1016/j.drugalcdep.2012.12.021 · Cited by 28
Identification of a new selective dopamine D4 receptor ligand
Sampson, D., Zhu, X. Y., Eyunni, S., Etukala, J. R., Ofori, E., Bricker, B. A., Lamango, N. S., Setola, V., Roth, B. L., & Ablordeppey, S. Y. (2014) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2014.04.026 · Cited by 27
Smoking Cessation
Patel, M. S., & Steinberg, M. B. (2016) · Annals of Internal Medicine · doi:10.7326/aitc201603010 · Cited by 28
Adverse events of smoking cessation treatments (nicotine replacement therapy and non-nicotine prescription medication) and electronic cigarettes in the Food and Drug Administration Adverse Event Reporting System, 2004−2016
Motooka, Y., Matsui, T., Slaton, R. M., Umetsu, R., Fukuda, A., Naganuma, M., Hasegawa, S., Sasaoka, S., Hatahira, H., Iguchi, K., et al. (2018) · SAGE Open Medicine · doi:10.1177/2050312118777953 · Cited by 27
Reprint of: Prevention and Treatment of Tobacco Use
Kalkhoran, S. M., Benowitz, N. L., & Rigotti, N. A. (2018) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2018.10.020 · Cited by 27
HIV and smoking: associated risks and prevention strategies
Manuel, J. I., Kariuki, W., Kariuki, N., Tuchman, E., O'Neal, J., & Lalanne, G. (2015) · HIV/AIDS - Research and Palliative Care · doi:10.2147/hiv.s56952 · Cited by 31
Documento de consenso para la atención clínica al tabaquismo en España
Guillem, F. C., Dalmau, R., Jiménez, L. C., Muñoz, J. L., Polo, A. L., & Ogué, M. C. P. (2012) · Medicina Clínica · doi:10.1016/j.medcli.2012.10.013 · Cited by 27
Smoking Cessation
Rennard, S. I., & Daughton, D. M. (2014) · Clinics in Chest Medicine · doi:10.1016/j.ccm.2013.11.002 · Cited by 25
Nicotine receptor partial agonists for smoking cessation
Cahill, K., Stead, L. F., Lancaster, T., & Polônio, I. B. (2012) · Sao Paulo Medical Journal · doi:10.1590/s1516-31802012000500014 · Cited by 25
Rapid Assessment of Cardiovascular Risk Among Users of Smoking Cessation Drugs Within the US Food and Drug Administration's Mini-Sentinel Program
Toh, S., Baker, M. A., Brown, J. S., Kornegay, C. J., Platt, R. G., & for the Mini-Sentinel Investigators (2013) · JAMA Internal Medicine · doi:10.1001/jamainternmed.2013.3004 · Cited by 24
Statistical controversies in clinical research: limitations of open-label studies assessing antiangiogenic therapies with regard to evaluation of vascular adverse drug events—a meta-analysis
Trone, J., Ollier, É., Chapelle, C., Bertoletti, L., Cucherat, M., Mismetti, P., Magné, N., & Laporte, S. (2018) · Annals of Oncology · doi:10.1093/annonc/mdy035 · Cited by 24
Effect of Early Initiation of Varenicline on Smoking Cessation in COPD Patients Admitted for Exacerbation: The Save Randomized Clinical Trial
Mao, R. L., Tromeur, C., Paleiron, N., Sanchez, O., Gagnadoux, F., Jouneau, S., Magnan, A., Vannimenus, C., Dansou, A., Proust, A., et al. (2019) · COPD Journal of Chronic Obstructive Pulmonary Disease · doi:10.1080/15412555.2019.1703928 · Cited by 23
Smoking Cessation in Patients With Acute Coronary Syndrome
Franck, C., Filion, K. B., & Eisenberg, M. J. (2018) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2018.01.017 · Cited by 23

Authors: Singh, S., Loke, Y. K., Spangler, J. G., & Furberg, C. D.
Affiliations: Johns Hopkins University (US)
ORCID: Singh, S.
Loke, Y. K.
Spangler, J. G.
Venue: Canadian Medical Association Journal
Publisher: CMA Joule Inc.
Published: 2011-07-04
Volume: 183
Issue: 12
Pages: 1359-1366
ISSN: 0820-3946 (ISSN-L)
1488-2329
DOI: 10.1503/cmaj.110218
PMC: PMC3168618
OpenAlex: W2160161905
Cited by: 286
References: 33
Citations by year: 2026: 3 · 2025: 4 · 2024: 4 · 2023: 2 · 2022: 3 · 2021: 6 · 2020: 7 · 2019: 8 · 2018: 12 · 2017: 18 · 2016: 23 · 2015: 29 · 2014: 31 · 2013: 52 · 2012: 56
FWCI: 5.63
Type: journal article
Language: en
Open access: gold
doi.org
Locations: Canadian Medical Association Journal (publishedVersion)
PubMed Central (publishedVersion)
PubMed (publishedVersion)
UEA Digital Repository (University of East Anglia) (submittedVersion)
Funders: National Center for Research Resources (KL2RR025006)
Topics: Health Sciences › Medicine › Public Health, Environmental and Occupational Health › Smoking Behavior and Cessation
Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Toxicology › Pharmacovigilance and Adverse Drug Reactions
Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Cardiac Health and Mental Health
Keywords: varenicline, cardiovascular adverse events, smoking cessation, nicotine replacement therapy, myocardial ischemia, cardiac arrhythmias, congestive heart failure, sudden death, tobacco users, drug safety
MeSH terms: Varenicline, Benzazepines, Cardiovascular Diseases, Humans, Product Surveillance, Postmarketing, Quinoxalines, Risk, Randomized Controlled Trials as Topic, Nicotinic Agonists

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Risk of serious adverse cardiovascular events associated with varenicline: a systematic review and meta-analysis

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Self-check

Citations

Cites

Cited by

Related

Metadata

Record

About these checks